Vaxcyte, Inc.
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to prevent bacterial diseases. The company leverages its proprietary XpressCF cell-free protein synthesis platform to engineer complex vaccines with enhanced immunological benefits beyond the… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vaxcyte, Inc. does
In the company’s own words
Vaxcyte, Inc. (NASDAQ: PCVX) is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to prevent bacterial diseases. The company leverages its proprietary XpressCF cell-free protein synthesis platform to engineer complex vaccines with enhanced immunological benefits beyond the capabilities of conventional cell-based manufacturing approaches. Unlike traditional methods that rely on random conjugation of antigens to protein carriers, Vaxcyte's site-specific conjugation technology enables precise control over attachment points, optimizing the exposure of critical immune epitopes and maximizing immune response while reducing carrier suppression effects.
The company's primary pipeline centers on pneumococcal conjugate vaccine (PCV) candidates targeting the approximately eight billion dollar global pneumococcal vaccine market. VAX-31, a 31-valent broad-spectrum PCV, represents the company's lead program and is designed to provide protection against both currently circulating and historically prevalent pneumococcal serotypes. VAX-31 has received FDA breakthrough therapy designation for prevention of invasive pneumococcal disease and pneumonia in adults and is currently in Phase 3 clinical development. VAX-24, a 24-valent PCV candidate, is in Phase 2 development for pediatric indications. VAX-XL represents a third-generation candidate designed to provide the broadest serotype coverage of any PCV in development.
Beyond its PCV franchise, Vaxcyte is developing VAX-A1, a novel conjugate vaccine candidate for Group A Streptococcus prevention, for which the company plans to initiate Phase 1 clinical studies in 2026. The company previously pursued VAX-GI for shigellosis prevention but paused advancement beyond preclinical development in August 2025 to prioritize resources toward its PCV franchise while preserving future development options.
Vaxcyte has established strategic manufacturing partnerships with Lonza, Sutro Biopharma, and Thermo Fisher Scientific to support clinical development and potential commercial-scale production. The company operates within the rapidly expanding global vaccine market, which is projected to reach approximately 115.77 billion dollars by 2033. More information is available at www.vaxcyte.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN CARLOS, CA
- Fiscal year end
- December
- CIK
- 1649094
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vaxcyte, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vaxcyte, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vaxcyte, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vaxcyte, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vaxcyte, Inc.'s last four quarterly filings that the numbers alone won't show?”